

AUSTRALIAN PRODUCT INFORMATION

ADRENALINE VIATRIS

adrenaline (epinephrine)* injection syringe auto-injector



1 NAME OF THE MEDICINE

** In some countries, adrenaline is known as epinephrine.*

Adrenaline (epinephrine)

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ADRENALINE VIATRIS adrenaline (epinephrine) injection contains adrenaline (epinephrine) 300 micrograms (0.3 mg) in 0.3 mL as the active ingredient.

Excipients with known effect: sulfites.

For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.

3 PHARMACEUTICAL FORM

Clear and colourless liquid

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

For the emergency treatment of anaphylaxis (acute severe allergic reactions) due to insect stings, or bites, foods, drugs or other allergens.

4.2 DOSE AND METHOD OF ADMINISTRATION

Dosage:

Selection of the appropriate dosage strength is determined according to patient body weight and this decision should be based on careful assessment of the individual patient and recognition of the life-threatening nature of reactions for which ADRENALINE VIATRIS is prescribed.

Adults (≥ 30 kg): Intramuscular injection of ADRENALINE VIATRIS Auto-Injector containing 0.3 mg adrenaline injection (0.3 mg/0.3 mL)

Children (15 to 30 kg): Intramuscular injection of ADRENALINE JR VIATRIS Auto-Injector containing 0.15 mg adrenaline injection (0.15 mg/0.3 mL)

The doctor or pharmacist may choose to recommend more or less than this amount**. With severe persistent anaphylaxis, repeat injections with an additional ADRENALINE VIATRIS Auto-Injector may be necessary.

To manage severe anaphylaxis, repeat ADRENALINE VIATRIS injections may be necessary. Each ADRENALINE VIATRIS Auto-Injector is used once only. The ADRENALINE VIATRIS dose may be repeated every 5 to 15 minutes if symptoms recur or have not subsided (see **Section 4.9 OVERDOSE**). It is recommended that patients are prescribed two ADRENALINE VIATRIS Auto-Injector pens which they should carry at all times.

Use of Adrenaline:

- The ADRENALINE VIATRIS Auto-Injector is intended for immediate self-administration. It is designed as emergency supportive therapy only and is not a replacement or substitute for subsequent medical or hospital care. The patient must consult a physician after injection in order to have relevant actions taken for further evaluation and/or treatment.

- Before using, check the medicine through the Auto-Injector viewing window and make sure the solution in the Auto-Injector is clear, colourless and free of particles. If it is discoloured or contains a precipitate, do not use, since these changes indicate that the effectiveness of the drug product may be decreased.
- The delivered dose of the ADRENALINE VIATRIS Auto-Injector should be injected intramuscularly into the anterolateral aspect of the thigh, not the buttock. It is designed to inject through clothing or directly through the skin. The ADRENALINE VIATRIS Auto-Injector should be pushed firmly into the outer mid-thigh until a “click” is heard or felt and it should then be held firmly against the thigh for approximately 3 seconds to ensure the dose is delivered. Instruct caregivers of young children who are prescribed an ADRENALINE VIATRIS Auto-Injector and who may be uncooperative and kick or move during an injection to hold the leg firmly in place and limit movement prior to and during an injection.
- DO NOT INJECT INTRAVENOUSLY. Every effort should be made to avoid inadvertent intravascular administration (see Section 4.9 OVERDOSE).
- **Appropriate steps should be taken to ensure that the patient thoroughly understands the indications and correct usage of this device. The ADRENALINE VIATRIS Auto-Injector should not be used for demonstration purposes. The healthcare professional, educator or caregiver should regularly review in detail with the patient, the package leaflet provided inside the ADRENALINE VIATRIS Auto-Injector carton, which includes usage instructions for the ADRENALINE VIATRIS Auto-Injector.**

Important Information - After Use:

- Patients should be instructed to dispose of the device safely after use by placing the used Auto-Injector in a sharps disposal unit.

4.3 CONTRAINDICATIONS

Contraindications are relative as this product is intended for use in life-threatening emergencies.

Adrenaline should not be used in patients with certain types of arrhythmia, cerebral arteriosclerosis and where vasopressor drugs are contraindicated e.g. thyrotoxicosis.

Adrenaline is also contraindicated in shock (other than anaphylactic shock) in patients or during general anaesthesia with halogenated hydrocarbons or cyclopropane.

Clinical conditions where special precautions are advised and interactions with other medicines are described in further detail in **Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE.**

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

A severe anaphylactic reaction is a life-threatening emergency and administration of ADRENALINE VIATRIS is not intended as a substitute for immediate medical care. In conjunction with the administration of adrenaline, the patient should seek immediate medical or hospital care. More than two sequential doses of adrenaline should only be administered under direct medical supervision.

The presence of anaphylactic shock should be confirmed before administering ADRENALINE VIATRIS, as ADRENALINE VIATRIS is only indicated for the treatment of anaphylaxis. Anaphylaxis may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhoea and abdominal cramps, involuntary voiding, wheezing, dyspnoea due to laryngeal spasm, pruritus, rashes, urticaria or angioedema.

For these reasons, Auto-Injectors should always be carried by such persons in situations of potential risk.

The patient/carer should be informed about the possibility of biphasic anaphylaxis which is characterised by initial resolution followed by recurrence of symptoms some time later.

DO NOT INJECT INTRAVENOUSLY as cerebral haemorrhage may occur due to a sharp rise in blood pressure. Rapidly acting vasodilators can counteract the marked pressor effects of adrenaline if there is such inadvertent administration.

Excipient warnings

ADRENALINE VIATRIS Auto-Injector contains sodium metabisulfite, a sulfite, which may itself cause allergic-type reactions including anaphylactic symptoms and bronchospasm in susceptible persons, especially those with a history of asthma. The alternatives to using adrenaline in a life-threatening situation may not be satisfactory. The presence of a sulfite in this product should not deter administration for serious allergic reactions even if the patient is sulfite-sensitive.

Patients with these conditions must be carefully instructed in regard to the circumstances under which ADRENALINE VIATRIS should be used.

Concomitant diseases

Use with caution in patients with ventricular fibrillation, cerebral arteriosclerosis, prefibrillatory rhythm, tachycardia, myocardial infarction, and phenothiazine-induced circulatory collapse.

Adrenaline should not be used in the presence of cardiac dilation.

Adrenaline causes ECG changes including a decrease in T-wave amplitude in all leads of normal persons. Caution should be taken when administering in the presence of cardiac dilation.

Adrenaline should be administered with caution in patients who have heart disease, including patients with cardiac arrhythmias, coronary artery or organic heart disease or hypertension.

Adrenaline can cause potentially fatal ventricular arrhythmias including fibrillation, especially in patients with organic heart disease or those receiving other drugs that sensitise the heart to arrhythmias (see **Section 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS**).

Anginal pain may be induced by adrenaline in patients with coronary insufficiency.

Use with caution in patients with pre-existing conditions whereby the use of vasopressor drugs is contraindicated (e.g. thyrotoxicosis).

Administer with caution to the elderly, and to individuals with diabetes, cardiovascular disease, hypertension, organic brain damage, severe renal impairment, prostatic adenoma leading to residual urine, hypercalcaemia, hypokalaemia, hyperthyroidism and psychoneurosis. In patients with Parkinsonism the drug increases rigidity and tremor.

In patients with high intraocular pressure in angle-closure glaucoma, adrenaline dilates the pupil (mydriasis) and produces an acute episode of angle-closure. Adrenaline reduces intraocular pressure in open-angle glaucoma, decreasing aqueous formation and increasing outflow facility.

Syncope has occurred following administration to asthmatic children.

ADRENALINE VIATRIS should not be injected into the hands, feet, ears, nose, buttocks or the genitalia as it may result in loss of blood flow to the affected area and may not provide effective treatment of anaphylaxis. Treatment should be directed at vasodilatation in addition to further treatment of anaphylaxis. If an accidental injection into one of these areas occurs, specialist medical advice must be sought immediately. Ensure the product is kept well clear of the face.

Additionally, injection into the buttock has been associated with Clostridial infections (gas gangrene). Cleansing with alcohol does not kill bacterial spores, and therefore, does not lower this risk.

Rare cases of serious skin and soft tissue infections, including necrotising fasciitis and myonecrosis caused by *Clostridia* (gas gangrene), have been reported at the injection site following adrenaline injection for anaphylaxis. *Clostridium* spores can be present on the skin and introduced into the deep tissue with subcutaneous or intramuscular injection. While cleansing with alcohol may reduce presence of bacteria on the skin, alcohol cleansing does not kill *Clostridium* spores. To decrease the risk of *Clostridium* infection, do not inject ADRENALINE VIATRIS into the buttock. Advise patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the adrenaline injection site.

In patients with a thick sub-cutaneous fat layer (> 20 mm skin to muscle distance under maximum compression), there is a risk for adrenaline not reaching the muscle tissue resulting in a suboptimal effect (see **Section 5.2 PHARMACOKINETIC PROPERTIES**). A second injection with an additional ADRENALINE VIATRIS may be needed in such individuals (see **Section 4.2 DOSE AND METHOD OF ADMINISTRATION**).

Hold leg firmly during injection. Lacerations, bent needles, and embedded needles have been reported when adrenaline has been injected into the thigh of young children who are uncooperative and kick or move during an injection. To minimise the risk of injection related injury when administering ADRENALINE VIATRIS to young children, instruct caregivers to hold the child's leg firmly in place and limit movement prior to and during injection.

Despite these concerns, adrenaline is essential for the treatment of anaphylaxis. Therefore, patients with these conditions, and/or any other person who might be in a position to administer ADRENALINE VIATRIS Auto-Injector to a patient experiencing anaphylaxis should be carefully instructed in regard to the circumstances under which adrenaline should be used.

Use in the Elderly

No data available.

Paediatric Use

No data available.

Effects on Laboratory Tests

No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Central nervous system and other medicines

The effects of adrenaline may be potentiated by tricyclic antidepressants, levothyroxine sodium, thyroid hormones, monoamine oxidase inhibitors (MAO inhibitors), catechol-O-methyl transferase inhibitors (COMT inhibitors), theophylline, oxytocin, parasympatholytics, some antihistamines (e.g. diphenhydramine, dexchlorpheniramine, chlorpheniramine and tripeleminamine), levodopa and alcohol.

Other sympathomimetic agents

Adrenaline should not be administered with other sympathomimetic agents because of the danger of additive effects and increased toxicity.

Alpha-adrenergic blocking agents

The vasoconstricting and hypertensive effects of adrenaline are antagonised by alpha-adrenergic blocking agents such as ergot alkaloids and phentolamine.

Beta-adrenergic blocking agents

Patients taking non-selective beta-blocking drugs when administered adrenaline for the treatment of an anaphylactic reaction may experience severe hypertension and bradycardia. The cardiostimulating and bronchodilating effects of adrenaline are antagonised by beta-adrenergic blocking drugs, such as propranolol. The risk of cardiac arrhythmias is higher when adrenaline is given to patients receiving digoxin or quinidine.

General anaesthetics

Halothane and other anaesthetics such as cyclopropane and trichlorethylene increase the risk of adrenaline-induced ventricular arrhythmias and acute pulmonary oedema if hypoxia is present.

Hypoglycaemic agents

Adrenaline-induced hyperglycaemia may lead to loss of blood sugar control in diabetic patients treated with hypoglycaemic agents. It may be necessary for diabetic patients receiving adrenaline to increase their dosage of insulin or oral hypoglycaemic drugs.

4.6 FERTILITY, PREGNANCY AND LACTATION**Effects on Fertility**

Studies of adrenaline after repeated exposure in animals to evaluate the effect on fertility have not been conducted. As adrenaline is a substance that naturally occurs in the body, it is unlikely that this drug would have any detrimental effects on fertility. This should not prevent the use of adrenaline under the conditions noted under **Section 4.1 THERAPEUTIC INDICATIONS**.

Use in Pregnancy

Pregnancy Category: A

Adrenaline has been given to a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed.

Adrenaline may delay the second stage of labour by inhibiting contractions of the uterus.

Use with caution in pregnant women whose maternal blood pressure is in excess of 130/80.

Use in Lactation

Adrenaline is not orally bioavailable. Adrenaline is excreted in breast milk but would not be expected to have any effect on the nursing infant.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

The patients' ability to drive and use machinery may be affected by the anaphylactic reaction, as well as by possible adverse effects to adrenaline.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Common symptomatic adverse events include anxiety, apprehensiveness, restlessness, tachycardia, respiratory difficulty, tremor, weakness, dizziness, headache, dyspnoea, cold extremities, sweating, pallor, nausea, vomiting, sleeplessness, hallucinations, palpitations, fear and flushing or redness of face and skin. Psychomotor agitation, disorientation, impaired memory and psychosis may occur.

Potentially fatal ventricular arrhythmias, including ventricular fibrillation may occur and severe hypertension may lead to cerebral haemorrhage and pulmonary oedema.

Angina may occur in patients with coronary artery disease.

Cardiac arrhythmias may lead to ventricular fibrillation and death.

Rare cases of stress cardiomyopathy have been reported in patients treated with adrenaline.

The potential for adrenaline to produce these types of adverse effects does not contraindicate its use in an acute life-threatening allergic reaction.

Accidental injection into the hands, fingers or feet may result in loss of blood flow to the affected area (see **Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE**). Adverse events experienced as a result may include increased heart rate, local reactions including injection site pallor, coldness or hypoaesthesia or injury at the injection site resulting in bruising, bleeding, discolouration, erythema or skeletal injury.

Lacerations, bent needles, and embedded needles have been reported when adrenaline has been injected into the thigh of young children who are uncooperative and kick or move during the injection (see **Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE**).

Rare cases of serious skin and soft tissue infections, including necrotising fasciitis and myonecrosis caused by Clostridia (gas gangrene), at the injection site have been reported from post-marketing experience. Injection into the buttock has resulted in cases of gas gangrene (see **Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE**).

Reporting Suspected Adverse Effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 OVERDOSE

Effects

Overdosage or inadvertent intravascular injection of adrenaline may cause cerebral haemorrhage resulting from a sharp rise in blood pressure. Fatalities may also result from pulmonary oedema because of peripheral vascular constriction together with cardiac stimulation.

Repeated administration of adrenaline can result in severe metabolic acidosis because of elevated blood concentration of lactic acid.

Treatment

Adrenaline is rapidly inactivated in the body and treatment of acute toxicity is mainly supportive. If necessary, the combined alpha and beta mediated effects of adrenaline may be counteracted by labetalol. Individually, alpha mediated effects may be counteracted by phentolamine whilst beta mediated effects may be counteracted by beta blocking agents.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of Action

Adrenaline is a sympathomimetic drug, acting on both alpha and beta receptors. Through its action on alpha adrenergic receptors, adrenaline lessens the vasodilatation and increased vascular permeability that occurs during anaphylaxis, which can lead to a loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, adrenaline causes bronchial smooth muscle relaxation that helps alleviate bronchospasm, wheezing and dyspnoea that may occur during anaphylaxis. Other major effects are increased systolic blood pressure, reduced diastolic pressure, tachycardia, hyperglycaemia and hypokalaemia. It is a powerful cardiac

stimulant, raising cardiac rate, cardiac output and coronary circulation. It has vasopressor properties, an antihistaminic action and is a bronchodilator. Adrenaline also alleviates pruritus, urticaria, and angioedema and may be effective in relieving gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxant effects on the smooth muscle of the stomach, intestine, uterus, and urinary bladder.

Clinical Trials

No data available.

5.2 PHARMACOKINETIC PROPERTIES

Absorption

The onset of action is rapid and of short duration. The plasma half-life of adrenaline is about 2.5 minutes. However, following subcutaneous or intramuscular administration, local vasoconstriction retards absorption, so that the effects occur insidiously and last much longer than the half-life would predict.

Distribution

Adrenaline is rapidly distributed to the heart, spleen, several glandular tissues and adrenergic nerves. It is approximately 50% bound to plasma proteins.

Metabolism

Adrenaline is rapidly inactivated in the liver and tissues mostly by the enzymes COMT and MAO. The liver is rich in these enzymes and is an important, although not essential, tissue in the degradation process.

Excretion

Up to 90% of the intravenous dose is excreted as metabolites in the urine. It crosses the placenta and is excreted in breast milk.

Clinical Trials

In a pharmacokinetic study in 35 healthy subjects, grouped by varying degrees of thickness in the subcutaneous fat layer of the thigh and stratified by gender, a single 0.3 mg/0.3 ml injection at the anterolateral aspect of the mid-thigh was made with an adrenaline Auto-Injector and was compared in crossover design to a manual syringe-delivered dose with needles individualized for delivery to muscle layer. The results indicate that female subjects with a thick sub-cutaneous fat layer (> 20 mm skin to muscle distance under maximum compression) had slower adrenaline absorption rate, reflected in a trend to lower plasma exposure in such subjects in the first ten minutes following injection. However, overall adrenaline exposure from 0 to 30 min ($AUC_{0-30min}$) for all groups of subjects receiving adrenaline Auto-Injector exceeded exposures resulting from syringe delivery.

Both inter-subject and intra-subject variability was however high in this study and therefore robust conclusions cannot be drawn.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Adrenaline and other catecholamines have been shown to have mutagenic potential *in vitro* and to be an oxidative mutagen in a WP2 bacterial reverse mutation assay. Adrenaline had a moderate degree of mutagenicity and was positive in the DNA Repair test with *B. Subtilis* (REC) assay but was not mutagenic in the *Salmonella* bacterial reverse mutation assay.

Studies of adrenaline after repeated exposure in animals to evaluate the mutagenic potential have not been conducted. This should not prevent the use of adrenaline under the conditions noted under **Section 4.1 THERAPEUTIC INDICATIONS**.

Carcinogenicity

Studies of adrenaline after repeated exposure in animals to evaluate the carcinogenic potential have not been conducted. This should not prevent the use of adrenaline under the conditions noted under **Section 4.1 THERAPEUTIC INDICATIONS**.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Hydrochloric acid (for pH adjustment), sodium chloride, sodium metabisulfite, water for injections.

6.2 INCOMPATIBILITIES

Adrenaline and its salts are physically incompatible with alkalis, metals, oxidising agents, sodium warfarin, hyaluronidase and many other drugs; it forms polymers with sodium bicarbonate.

Oxidation can be inhibited by addition of anti-oxidants. The solution darkens in colour upon exposure to air or light.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Adrenaline is light sensitive and should be stored in the carrier tube provided. The carrier tube is not waterproof.

Store below 25°C. Temperature excursions between 15°C to 25°C permitted.

Do not refrigerate. Protect from light.

Before using, check periodically through the viewing window of the Auto-Injector to make sure the solution is not discoloured. Replace the Auto-Injector if the solution is discoloured or contains a precipitate.

6.5 NATURE AND CONTENTS OF CONTAINER

The ADRENALINE VIATRIS Auto-Injector contains 2 mL Adrenaline Injection USP 0.3 mg/0.3 mL and delivers a single 300 micrograms adrenaline dose.

ADRENALINE VIATRIS Auto-Injector is available in a single pack or in a pack of 2.

Not all pack sizes may be marketed.

Australian Register of Therapeutic Goods (ARTG)

AUST R 296842 – ADRENALINE VIATRIS adrenaline (epinephrine) 0.3mg/0.3mL injection syringe auto-injector

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL


In Australia, any unused medicine or waste material should be disposed of by taking it to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Chemical Structure

Chemical name: (R)-1-(3,4-dihydroxyphenyl)-2-methylaminoethanol

Structural formula:



Molecular formula: $C_9H_{13}NO_3$

Molecular weight: 183.2

CAS Number

CAS Registry No: 51-43-4

Adrenaline is a white odourless crystalline powder, soluble in solutions of mineral acids and alkalis.

Adrenaline solution deteriorates rapidly on exposure to air or light, turning pink from oxidation to adrenochrome and brown from the formation of melanin. Replace the ADRENALINE VIATRIS Auto-Injector if the adrenaline solution appears discoloured.

ADRENALINE VIATRIS has a pH range of 2.2-5.0.

7 MEDICINE SCHEDULE (POISONS STANDARD)

S3 (Pharmacist Only Medicine)

8 SPONSOR

Alphapharm Pty Ltd trading as Viatris

Level 1, 30 The Bond

30 – 34 Hickson Road

Millers Point NSW 2000

www.viatris.com.au

Phone: 1800 274 276

9 DATE OF FIRST APPROVAL

1 March 2018

10 DATE OF REVISION

16 April 2025

Made in USA

****Australasian Society of Clinical Immunology and Allergy Guidelines - Adrenaline (Epinephrine) Injector Prescription, ASCIA 2024** <https://www.allergy.org.au/hp/anaphylaxis/adrenaline-injector-prescription>.

Summary Table of Changes

Section Changed	Summary of New Information
All	Minor editorial change
4.2, 4.8	Editorial changes for improved readability
4.4	Additional safety updates on the possibility of biphasic reaction and for patients with high intraocular pressure
4.5	Updated drug interactions

ADRENALINE VIATRIS_pi\Apr25/00 (CCDS 22-Nov-2024)